News >

Strategies Evolve for Overcoming EGFR-TKI Resistance in NSCLC

Caroline Seymour
Published: Thursday, May 16, 2019

Lyudmila A. Bazhenova, MD
Lyudmila A. Bazhenova, MD
Pending overall survival (OS) data from the phase III FLAURA trial, osimertinib (Tagrisso) may be the preferred frontline treatment for patients with EGFR-mutant non–small cell lung cancer (NSCLC), said Lyudmila A. Bazhenova, MD. However, treatment beyond progression on the agent will require more consideration, especially in the face of heterogenous resistance mechanisms.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication